Related Experiment Video
Updated: May 21, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
[Development of therapeutic antibodies for gastric and colorectal cancers]
Tian-tian Zhao1, Na-na Fan, Li Lin
1Department of Biochemistry and Genetics, Zhejiang University School of Medicine, Hangzhou 310058, China.
Abstract:
With the elucidation of structures and functions, antibodies are widely applied in the diagnosis and treatment of diseases. Today, therapeutic antibodies have played ever increasing roles in the treatment of cancers. In fact, there are over 20 monoclonal antibodies which have been approved by the U.S.Food and Drug Administration (FDA) for the therapeutic use in cancers. For the gastric and colorectal cancers, there are at least 9 antibodies have been approved for cancer therapy or for clinical trials. These antibody drugs target to tumor associate antigens and can destroy the cancer cells through several mechanisms such as antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, blockage of blood nutrition and crucial signaling pathways. With the progress in gene engineering technology, the diverse structures of antibodies can be created. In addition, the antibody-conjugates with radioisotopes, toxins and cytotoxins, are also designed for targeted therapy of gastric and colorectal cancers. In this article, we review the trends in the clinical development and application of antibody drugs for future research and development of the rapidly expanding therapeutic modality in gastric and colorectal cancers.
Insights
Therapeutic antibodies are increasingly vital for treating cancers, with over 20 FDA-approved options. This review highlights antibody drug development for gastric and colorectal cancers, including novel antibody-conjugates.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Context:
- Antibodies are crucial in disease diagnosis and treatment.
- Therapeutic antibodies are increasingly used for cancer therapy, with over 20 FDA-approved monoclonal antibodies.
- Specifically, nine antibodies are approved or in clinical trials for gastric and colorectal cancers.
Purpose:
- To review the clinical development and application trends of antibody drugs for gastric and colorectal cancers.
- To explore future research and development directions for antibody-based cancer therapies.
Summary:
- Antibody drugs target tumor-associated antigens, employing mechanisms like antibody-dependent cell cytotoxicity and complement-dependent cytotoxicity to eliminate cancer cells.
- Advanced gene engineering enables diverse antibody structures, including antibody-conjugates with radioisotopes or toxins for targeted cancer therapy.
- The review focuses on the evolving landscape of antibody therapeutics for gastric and colorectal malignancies.
Impact:
- Provides insights into the current state and future trajectory of antibody drug development in oncology.
- Informs researchers and clinicians about the potential of antibody-based targeted therapies for gastric and colorectal cancers.
- Highlights the significance of antibody engineering and conjugation technologies in advancing cancer treatment modalities.
Related Concept Videos
01:26Gastritis II: Pathophysiology
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...